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INHIBITION OF LIVER, KIDNEY, AND INTESTINE REGENERATION BY RAPAMYCIN, ,2 
For a decade, liver transplant recipients have been treated 
with cyclosporine, a drug with modest hepatotoxicity (1). Con-
cern that CsA might inhibit hepatic regeneration or the ability 
of the transplanted liver to adjust its size to that of the recipient 
prompted studies by Makowka et a1. (2) and others (3-5), 
which showed that regeneration actually was enhanced. A 
newer unrelated immunosuppressive agent, FK506, has the 
same properties (5). In addition, these 2 drugs have other 
actions that are collectively called hepatotrophic. The increase 
in hepatocyte replication that is caused by portacaval shunt in 
dogs is more than doubled by intrahepatic infusion of either of 
these drugs via the tied-off central portal vein, and the expected 
atrophy and organelle disruption is prevented (6, 7). Direct 
experimentation in nude rats has ruled out immune modulation 
of lymphocytes and NK cells as an explanation (8). 
These observations have contributed to a hypothesis that 
CsA and FK506 modify signal transduction in a variety of cells, 
not limited to those of the immune system (7, 9, 10), and 
including signaling pathways associated with growth contro!' If 
this were true, it would explain the remarkable spectrum of 
adverse as well as desired effects of these agents. Important 
elements in this hypothesis included the discovery that the 
cytosolic receptors for FK506 and rapamycin (FK506-binding 
protein, FKBP) and cyclosporine (cyclophilin) are distinct 
proteins that exhibit peptidyl-prolyl cis trans isomerase (rota-
mase) activity (11, 12) and that these small-molecular-weight 
cytoplasmic proteins are in virtually all cells in the body, as 
well as in the nuclei of some (13, 14). 
How these 3 drugs (cyclosporine, FK506, and rapamycin) 
block or modify signaling pathways (15) is not understood. 
Rotamases have been shown to facilitate protein folding (16, 
17) and catalyze the interconversion of rotamers of peptidyl-
prolyl bonds in vitro (18, 19), but the inhibition of this enzy-
matic activity is not related to the action of these drugs on T 
lymphocytes (20). The fact that signal transduction in T-
lymphocytes is blocked in different ways by FK506 and rapa-
mycin (20, 21) is of great interest, particularly because these 2 
drugs are chemically related and have the same binding site 
(FKBP). Consequently, the hepatotrophic qualities of rapa-
mycin were determined with the same dog and rat test models 
as had been used previously to test CsA, FK506 (2-7), and 
recombinant FKBP (22). In addition, the influence of rapa-
mycin on renal and intestinal regeneration was determined. 
The results with rapamycin were profoundly different from 
those observed previously with the other 2 drugs. 
The dogs underwent a completely diverting portacaval shunt. 
Immediately afterwards, an infusion catheter was inserted into 
the tied-off left portal vein for pump-driven constant infusion 
of the rapamycin over the next 4 days in the doses shown in 
Table 1. At the end of 4 days, the animals were injected with 
0.2 MCijkg intravenous 3H thymidine (New England Nuclear, 
Boston), and killed 2 hr later. Specimens were obtained for 
comparison of the hepatocytes in the left (infused) and right 
(not infused) liver lobes using previously described morpho-
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2 The rapamycin was a gift from Dr. Joseph Y. Chang of the Wyeth-
Ayerst Research Company, Princeton, New Jersey. 
metric and autoradiographic techniques (6, 7). There was no 
effect (Table 1) on the hepatocyte atrophy and the increased 
hepatocyte renewal that are characteristic after Eck fistula and 
that are prevented both by cyclosporine (6) and by FK506 (7). 
For the regeneration experiments, fasted adult male inbred 
Fisher 344 rats weighing 180-200 g (Hilltop Lab Animals Inc., 
Scottsdale, P A) were assigned to groups, given water and food 
for 4 days, and treated daily with vehicle or rapamycin. On the 
fourth day, between 0900 and 1030, groups 2-5 underwent 70% 
hepatectomy under light ether anesthesia (5). Rats of groups 7 
and 8 had right nephrectomy (2), and those in group 10 and 11 
had a 40% resection of small intestine excluding the jejunum. 
Twenty-four hr after the operations or control period, 50 MCi-
3H-thymidine was administered by intraperitoneal injection. 
The rats were killed 2 hr later by guillotine. Hepatic DNA 
synthesis and liver mitosis, kidney DNA synthesis and small 
bowel DNA synthesis were performed as described previously 
in cyclosporine and FK506 experiments (5,23). 
Hepatic regeneration was significantly inhibited by RPM 
with a dose relationship so that at 1.0 mg/kg the normal 
response was virtually eliminated (Table 2). Regeneration of 
the kidney and intestine was significantly inhibited with the 
intermediate dose of 0.3 mg/kg/day (Table 3). 
These results add to the significance of the previous dem-
onstration that rapamycin affects T-Iymphocytes differently 
than FK506 (20,21) and lend support to the view ofrapamycin 
as an inhibitor of growth factor receptor-associated signaling 
pathways. Instead of promoting liver regeneration and having 
the other hepatotrophic qualities common to FK506 and cyclo-
sporine, rapamycin was antihepatotrophic. In rats submitted 
to hepatectomy, it inhibited instead of augmenting liver regen-
eration and in dogs submitted to Eck fistula it did not prevent 
the hepatocyte atrophy and organelle disruption that are caused 
by this operation but prevented by cyclosporine(6) and FK506 
(7). The observations in rats constitute the first physiologic 
evidence that the immunophilin network that is thought to be 
pleiotropic in its metabolic, immunologic, and growth control 
actions may be involved in countervailing (opposite effects) 
regulatory processes. Regeneration of the kidney and intestine 
was also retarded by RPM administration, indicating that the 
growth-inhibitory effect of RPM is not liver-specific. 
This suggests that rapamycin, a profound immunosuppres-
sant, also should be examined as an antitumor agent. The 
implications are obvious in general and in transplantation in 
particular. Efforts to treat primary hepatic malignancies by 
total hepatectomy and liver transplantation have been plagued 
by a high rate of tumor recurrence. There might be a possibility 
of treating these patients or others whose extirpative proce-
dures have been done for the reason of malignancy (24) with a 
drug that could prevent both rejection and tumor cell replica-
tion. Striking antineoplastic properties of rapamycin against a 
variety of mouse tumors (25) and against human tumors trans-
planted into nude mice (26, 27) have been described. 
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TABLE 1. Hepatocyte size and mitosis in dogs after ECK fistula with continuous intraportal infusion of rapamycin 
Rapamycin Mitosis (No. labels hepato- Cell size (units)a 
Group No. dogs (mg/kg/ cytes per 1000 hepatocytes)a P P 
day) Right lobe Left lobe Right lobe Left lobe 
1 5 0 4.2±0.33 4.4±0.2 0.1043±0.018 0.1102±0.016 
2 2 0.1 4.2±OA 4.1±0.5 NS 0.1046±0.01 0.1062±0.O8 NS 
3 2 0.5 3.9±0.2 3.9±0.Ol NS 0.1018±0.009 0.1018±0.01 NS 
a Mean ± SD. 
TABLE 2. Effect of preoperative intramuscular rapamycin for 4 days on rat liver regeneration 
Dose/day DNA synthesis % Hepatocytes Group No. rats (mg/kg) Hepatectomy (xI03 c.p.m./ in mitosis P MGDNA) 
1 5 3.5±OA 1.7±0.1 
2 10 70% 185±13.0 33A±3.20 
3 10 0.1 70% 92±8.5 16.8±4.2 <0.05 vs. 2 
4 10 0.3 70% 40±6.2 11.2±3.3 <0.005 vs. 2 
5 10 1.0 70% 3.5±3.5 4.8±0.5 <0.005 vs. 2 
TABLE 3. [3H]-thymidine incorporation in kidney and small intestine from normal, nephrectomized, or small intestine-resected rats treated or 
not treated for 4 preoperative days with rapamycin (0.3 mg/kg/day i.m.) 
DNA synthesis 
Group n Treatment Surgery (XI03/c.p.m./ .p 
mgDNA) 
6 5 Vehicle No 2A±0.2 
7 5 Vehicle Unilateral nephrectomy 3.8±2.3 
8 5 RPM Unilateral nephrectomy 0.5±0.01 <0.0005 vs. 7 
9 5 Vehicle No 17.2±2.3 
10 5 Vehicle 40% Small-intestine re- 62.3±10A 
section 
11 5 RPM 40% Small-intestine re- 29.3±5.1 <0.05 vs. 10 
K. A. PORTER 
S. L. SCHREIBER 
Department of Surgery 
University Health Center of Pittsburgh 
University of Pittsburgh 
Veterans Administration Medical Center 
Pittsburgh, Pennsylvania 
Department of Gastroenterology 
University of Bari 
Bari, Italy 
Department of Pathology 
St. Mary's Hospital and Medical School 
London, England 
Department of Chemistry 
Harvard University 
Cambridge, Massachusetts 
section 
3 Address correspondence to: Thomas E. Starzl, M.D., Ph.D., De-
partment of Surgery, 3601 Fifth Avenue, University of Pittsburgh, 
Pittsburgh, PA 15213. 
REFERENCES 
1. Klintmalm GBG, Iwatsuki S, Starzl TE. Cyclosporin A hepato-
toxicity in 66 renal allograft recipients. Transplantation 1981; 
32: 488. 
2. Makowka L, Svanas G, Esquivel C, et al. The effect of cyclosporine 
on hepatic regeneration. Surg Forum 1986; 37: 352. 
3. Kahn D, Lai HS, Romovacek H, Makowka L, Van Thiel D, Starzl 
TE. Cyclosporin A augments the regeneration response after 
partial hepatectomy in the rat. Transplant Proc 1988; 20 (suppl 
3): 850. 
4. Kim YI, Caine RY, Nagasue N. Cyclosporine A stimulates prolif-
eration of the liver cells after partial hepatectomy in rats. Surg 
Gynecol Obstet 1988; 166: 317. 
5. Francavilla A, Barone M, Todo S, Zeng Q, Porter KA, Starzl TE. 
Augmentation of rat liver regeneration by FK 506 compared with 
cyclosporine. Lancet 1989; 1: 1248. 
6. Mazzaferro V, Porter KA, Scotti-Foglieni CL, et al. The hepato-
trophic influence of cyclosporine. Surgery 1990; 107: 533. 
7. Starzl TE, Porter KA, Mazzaferro V, Todo S, Fung J, Francavilla 
A. Hepatotrophic effects ofFK506 in dogs. Transplantation 1991; 
51: 67. 
8. Francavilla A, Starzl TE, Barone M, et al. Studies on mechanisms 
of augmentation of liver regeneration by cyclosporine and FK 
506. Hepatology 1991; 14: 140. 
9. Starzl TE, Fung JJ, Todo S. Contempo 90: transplantation. JAMA 
1990; 263: 2686. 
10. Schreiber SL. Chemistry and biology of the immunophilins and 
their immunosuppressive ligands. Science 1991; 251: 283. 
11. Harding MW, Galat A, Uehling DE, Schreiber SL. A receptor for 
the immunosuppressant FK506 is a cis-trans peptidyl-prolyl 
isomerase. Nature 1989; 341: 758. 
12. Siekierka JJ, Hung SHY, Poe M, Lin CS, Sigal NH. A cytosolic 
binding protein for the immunosuppressant FK 506 has peptidyl-
prolyl isomerase activity but is distinct from cyclophilin. Nature 
1989; 341: 755. 
13. Marks WH, Harding MW, Handshumacher R, Marks C, Lorber 
MI. Cyclophilin, the cyclosporine receptor: immunochemical dis-
498 TRANSPLANTATION Vol. 53, No.2 
tribution in normal mammalian tissues. Transplantation 1991; 
52: 340. 
14. Ryffel B, Woerly G, Greiner B, Haendler B, Mihatsch MJ, Foxwell 
BMJ. Distribution of the cyclosporine binding protein cyclo-
philin in human tissues. Immunology 1991; 72: 399. 
15. Hultsch T, Rodriguez JL, Kaliner MA, Hohman RJ. Cyclosporin 
A inhibits degranulation of rat basophilic leukemia cells and 
human basophils. J Immunol 1990; 144: 2659. 
16. Fischer G, Bang J. The refolding of urea -denatured ribonuclease A 
is catalyzed by peptidyl-prolyl cis-trans isomerase. Biochim Bio-
phys Acta 1984; 828: 39. 
17. Tropschug M, Wachter E, Mayer S, Schonbrunner ER, Schmid 
FX. Isolation and sequence of an FK506-binding protein from 
N. crassa which catalyses protein folding. Nature 1990; 346: 674. 
18. Fischer G, Wittmann-Liebold B, Kiefhaber T, Schmid FX, Lang 
K. Cyclophilin and peptidyl-prolyl cis-trans isomerase are prob-
ably identical proteins. Nature 1990; 337: 476. 
19. Albers MW, Walsh CT, Schreiber SL. Substrate specificity for the 
human rotamase FKBP: a view of FK 506 and rapamycin as 
leucine-(twisted amide)-proline mimics. J Org Chern 1990; 55: 
4984. 
20. Bierer BE, Mattila PS, Standaert RF, et a1. Two distinct signal 
transmission pathways in T lymphocytes are inhibited by com-
plexes formed between an immunophilin and either FK 506 or 
rapamycin. Proc Natl Acad Sci USA 1990; 87: 9231. 
21. Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH. 
Distinct mechanisms of suppression of murine T cell activation 
by the related macrolides FK 506 and rapamycin. J Immunol 
1990; 144: 251. 
22. Starzl TE, Schreiber SL, Albers MW, Porter KA, Foglieni CS, 
Francavilla A. Hepatotrophic properties in dogs of human FKBP, 
the binding protein for FK506 and rapamycin. Transplantation 
1991; 52: 751. 
23. Francavilla A, Barone M, Starzl TE, et al. FK 506 as a growth 
control factor. Transplant Proc 1990; 23: 90. 
24. Starzl TE, Todo S, Tzakis A, et al. Abdominal organ cluster 
transplantation for the treatment of upper abdominal malignan-
cies. Ann Surg 1989; 210: 374. 
25. Eng CP, Sehgal SN, Veznia C. Activity of rapamycin (AY-22,989) 
against transplanted tumors. J Antibiot (Tokyo) 1984; 37: 1231. 
26. Houchens DP, Ovejera A, Riblet SM, Slagel DE. Human brain 
tumor xenografts in nude mice as a chemotherapy model. Eur J 
Cancer Clin Oncol 1983; 19: 799. 
27. Fiebig H-H, Berger DP, Winterhalter BR, Plowman J. In vitro and 
in vivo evaluation of US-NCI compounds in human tumor xen-
ografts. Cancer Treat Rev 1990; 17: 109. 
Received 21 March 1991. 
Accepted 9 May 1991. 
